08:00 , Nov 23, 2009 |  BC Week In Review  |  Company News

Crucell sales and marketing update

Crucell launched the global Crucell brand. The company will phase out the use of brand names Berna Biotech Ltd. , SBL Vaccines AB and Berna Products Corp. Crucell acquired all three companies in 2006 (see...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

Flavimun yellow fever vaccine regulatory update

Crucell disclosed that in March it submitted a marketing application in Switzerland for Flavimun yellow fever vaccine. The company expects to submit an application for the live attenuated vaccine in Germany by year end. Crucell...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

Hepavax-Gene regulatory update

Crucell received Chinese marketing approval for its Hepavax-Gene recombinant HBV vaccine to prevent HBV infection. The company plans to launch the vaccine next year. Crucell obtained rights to the vaccine through its 2006 acquisition of...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Company News

Crucell, Zydus deal

Zydus acquired Crucell's Etna Biotech s.r.l. subsidiary for an undisclosed sum. The deal includes a preclinical vaccine portfolio including an HBV vaccine that uses Crucell's virosome vaccine technology, a nasal vaccine to prevent influenza and...
07:00 , Oct 6, 2008 |  BioCentury  |  Finance

4Q milestones

4Q milestones Company Product Indication Event Milestone Acura (NASDAQ:ACUR)/ King (NYSE:KG) Acurox (formerly OxyADF) Moderate to severe pain Submit NDA YE08 Acusphere (NASDAQ:ACUS)/ Nycomed Imagify Detect coronary heart disease (CHD) Submit MAA 4Q08 Addrenex/Sciele (NASDAQ:SCRX,...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Clinical News

Flavimun yellow fever vaccine regulatory update

Crucell plans to postpone Swiss registration of its Flavimun yellow fever vaccine that had been slated for this year. The company said the decision was made in order to devote the same manufacturing facility to...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Company News

Crucell, Pevion Biotech Ltd. deal

Crucell N.V. (Euronext:CRXL; CRXL), Leiden, the Netherlands   Pevion Biotech Ltd. , Bern, Switzerland   Business: Infectious   CRXL's Berna Biotech AG subsidiary sold its 36% stake in Pevion to other Pevion shareholders for CHF10...
07:00 , May 7, 2007 |  BioCentury  |  Finance

Global visibility

On the face of it, Europe seems to have all the pieces in place. Capital is available from public and private sources, there are clusters of world class science and technology, companies have been able...
08:00 , Dec 4, 2006 |  BC Week In Review  |  Company News

Crucell sales and marketing update

CRXL co-developed Quinvaxem with Chiron, which is now part of Novartis AG (NVS; SWX:NOVN, Basel, Switzerland). The company got Hepavax-Gene through its acquisition of Berna Biotech Ltd. earlier this year (see BioCentury, May 29). Crucell...
08:00 , Dec 4, 2006 |  BioCentury  |  Strategy

Crucell chronicles

Crucell chronicles Weekly stock price for Crucell (Euronext:CRXL; CRXL) on Euronext Amsterdam tracked against selected events since 2000. 6/30/00 - IntroGene and U-BiSys merge and change name to CrucellA. 10/27/00 - Raises E144M ($119M) in...